The estimated Net Worth of Mardi Dier is at least $7.2 Milión dollars as of 14 October 2022. Ms Dier owns over 1,629 units of Ultragenyx Pharmaceutical stock worth over $3,756,929 and over the last 16 years she sold RARE stock worth over $3,228,710. In addition, she makes $216,346 as Exec. VP & CFO at Ultragenyx Pharmaceutical.
Sign up
Ms Dier RARE stock SEC Form 4 insiders trading
Ms has made over 26 trades of the Ultragenyx Pharmaceutical stock since 2008, according to the Form 4 filled with the SEC. Most recently she sold 1,629 units of RARE stock worth $65,421 on 14 October 2022.
The largest trade she's ever made was exercising 93,392 units of Ultragenyx Pharmaceutical stock on 27 June 2017 worth over $1,736,157. On average, Ms trades about 5,060 units every 77 days since 2008. As of 14 October 2022 she still owns at least 66,695 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Ms Dier stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Mardi C. Dier biography
Mardi C. Dier is the Exec. VP & CFO at Ultragenyx Pharmaceutical.
What is the salary of Ms Dier?
As the Exec. VP & CFO of Ultragenyx Pharmaceutical, the total compensation of Ms Dier at Ultragenyx Pharmaceutical is $216,346. There are 18 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
How old is Ms Dier?
Ms Dier is 57, she's been the Exec. VP & CFO of Ultragenyx Pharmaceutical since . There are 11 older and 13 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
What's Ms Dier's mailing address?
Mardi's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805.
Insiders trading at Ultragenyx Pharmaceutical
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr a Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
What does Ultragenyx Pharmaceutical do?
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
What does Ultragenyx Pharmaceutical's logo look like?
Complete history of Ms Dier stock trades at Adamas Pharmaceuticals Inc, Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Oric Pharmaceuticals a Prelude Therapeutics Inc
Ultragenyx Pharmaceutical executives and stock owners
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include:
-
Emil Kakkis,
President, Chief Executive Officer, Director -
Dennis Huang,
Chief Technical Operations Officer, Executive Vice President -
John Pinion,
Chief Quality Officer and Executive Vice President of Translational Sciences -
Camille Bedrosian,
Chief Medical Officer and Executive Vice President -
Thomas Kassberg,
Chief Business Officer, Executive Vice President -
Karah Parschauer,
Executive Vice President, General Counsel -
Dr. Emil D. Kakkis M.D., Ph.D.,
Pres, CEO & Director -
Shehnaaz Suliman,
Independent Director -
Dr. Camille L. Bedrosian M.D.,
Chief Medical Officer & Exec. VP -
Erik Harris,
Exec. VP & Chief Commercial Officer -
John Richard Pinion II,
Chief Quality Operations Officer & Exec. VP of Translational Sciences -
Daniel Welch,
Independent Chairman of the Board -
Matthew Fust,
Independent Director -
William Aliski,
Independent Director -
Michael Narachi,
Independent Director -
Lars Ekman,
Independent Director -
Clay Siegall,
Independent Director -
Deborah Dunsire,
Independent Director -
Mardi C. Dier,
Exec. VP & CFO -
Mardi Dier,
Chief Financial Officer, Executive Vice President -
Ernie Meyer,
Chief Human Resource Officer, Executive Vice President -
Erik Harris,
Executive Vice President and Chief Commercial Officer -
Ernie W. Meyer,
Chief HR Officer & Exec. VP -
Karah Herdman Parschauer J.D.,
Gen. Counsel & Exec. VP -
Danielle Keatley,
Sr. Director of Investor Relations & Corp. Communications -
Dennis Karl Huang,
Chief Technical Operations Officer & Exec. VP -
Theodore A. Huizenga,
VP, Corp. Controller & Principal Accounting Officer -
Sunil Agarwal,
Chief Medical Officer -
Jayson Donald Alexander Dallas,
See Remarks -
Wladimir Hogenhuis,
Chief Operating Officer -
Llc Fmr,
10% owner -
Marten Steen,
Director -
Group Holdings (Sbs) Adviso...,
-
Eran Nadav,
Director -
Amrit Ray,
-
Shalini Sharp,
EVP, Finance -
Corazon (Corsee) D. Sanders,
-
Theodore Alan Huizenga,
SVP, Chief Accounting Officer -
Eric Crombez,
EVP and Chief Medical Officer -
Howard Horn,
Chief Financial Officer